Form 8-K - Current report:
SEC Accession No. 0001824293-26-000030
Filing Date
2026-01-30
Accepted
2026-01-29 20:22:30
Documents
17
Period of Report
2026-01-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K val-20260129.htm   iXBRL 8-K 27852
2 EX-5.1 gri-atmx51opinionjanuary29.htm EX-5.1 14186
3 EX-10.1 gri-atmx8xkex101amendmentn.htm EX-10.1 17150
7 image_1.jpg GRAPHIC 10797
8 val-20260129_g1.jpg GRAPHIC 16879
9 val-20260129_g2.jpg GRAPHIC 1656
  Complete submission text file 0001824293-26-000030.txt   231903

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT val-20260129.xsd EX-101.SCH 1794
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT val-20260129_lab.xml EX-101.LAB 23449
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT val-20260129_pre.xml EX-101.PRE 13590
19 EXTRACTED XBRL INSTANCE DOCUMENT val-20260129_htm.xml XML 2815
Mailing Address 2223 AVENIDA DE LA PLAYA SUITE 208 LA JOLLA CA 92037
Business Address 2223 AVENIDA DE LA PLAYA SUITE 208 LA JOLLA CA 92037 (619) 400-1171
GRI Bio, Inc. (Filer) CIK: 0001824293 (see all company filings)

EIN.: 824369909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40034 | Film No.: 26580062
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)